ストックスクリーナーアプリを入手
2.55
0.00%
0.00
アフターアワーズ：
2.55
Kiora Pharmaceuticals Inc (KPRX) 最新ニュース
Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Stock Price, News & Analysis - Kalkine
Chong Kun Dang Wins Korean Rights to Kiora Retinal Drug - en.sedaily.com
Kiora licenses KIO-301 rights in South Korea - grafa.com
Kiora Licenses South Korean KIO-301 Rights for $1M Upfront - Minichart
Kiora PharmaceuticalsEligible for Double D - Moomoo
Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Nigeria
Kiora Licenses KIO-301 Rights in South Korea - TipRanks
Kiora Pharmaceuticals Licenses KIO-301 South Korea Rights to Chong Kun Dang for $1 Million Upfront Plus Milestones and Royalties - kalkine.ca
Perceptive Advisors LLC Acquires New Position in Kiora Pharmaceuticals Inc (KPRX) - GuruFocus
ADAR1 group discloses 9.9% Kiora Pharmaceuticals (KPRX) stake via shares and warrants - Stock Titan
Nantahala Capital discloses 9.99% Kiora Pharmaceuticals (KPRX) stake via 13G/A filing - Stock Titan
KPRX Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesReturn On Capital - Vinanet
Kiora Pharmaceuticals (KPRX) reports 9.99% stake held by Perceptive group - Stock Titan
Form 8K Kiora Pharmaceuticals Inc For: 7 August By Investing.com - Investing.com Nigeria
Kiora Pharmaceuticals advances retinal disease trials, secures $24M funding, expects data in 2027 - Pluang
Kiora Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kiora Pharmaceuticals Reports Q2 2026 Results, Advances KIO-301 and KIO-104 Trials With Runway Into Late 2028 - kalkine.ca
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - TMX Newsfile
Kiora Pharmaceuticals (KPRX) Gains 2.83% as Shares Approach $2.67 ResistanceGap and Reverse - dars.gov.et
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kiora Pharmaceuticals Market Sentiment - Benzinga España
Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KPRX|Kiora Pharmaceuticals Inc|Price:2.530|Chg%:-0.020 - TradingKey
TradingKey - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kiora Pharmaceuticals Q1 2026 Earnings: EPS Beat as Pre‑Revenue Biotech Narrows Loss ExpectationsPerformance Review - dars.gov.et
Kiora Pharmaceuticals (KPRX) Edges Higher as Shares Test Key ResistanceKAMA Signal - dars.gov.et
Kiora Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:KPRX - TradingView
Kiora Pharmaceuticals Inc (KPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kiora Pharmaceuticals (KPRX) Slips 2.7% as Biotech Sector Faces Renewed PressureThematic ETF Flow - vinanet.vn
Price to sales forward of Kiora Pharmaceuticals, Inc. – FWB:7EY - TradingView
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – FWB:7EY - TradingView
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – LS:A40EG5 - TradingView
Kiora Pharmaceuticals Inc. (KPRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – GETTEX:7EY - TradingView
Price to earnings forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
Price to book forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
Enterprise value to EBITDA forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
KPRXKiora Pharmaceuticals Inc Latest SEC Filings - Finviz
Form 4 Kiora Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com India
Kiora (NASDAQ: KPRX) CFO uses 911 shares to cover tax obligations - Stock Titan
[Form 4] KIORA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Kiora Pharmaceuticals (KPRX) Holds Steady Near Support as Biotech Sector WatchesRelative Volume - dars.gov.et
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium - TMX Newsfile
Kiora Pharmaceuticals Inc Warrant 2022-27.09.27 on Kiora Pharma A Financial Disclosures & SEC Filings - TradingView
Kiora Pharmaceuticals (KPRX) Slides Marginally as Biotech Sector Remains CautiousMonthly Profile - po-news-eg.net
Kiora Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:KPRX) - TradingView
KPRX Forecast — Price Target — Prediction for 2027 - tradingview.com
7EY Forecast — Price Target — Prediction for 2027 - TradingView
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
Kiora Pharmaceuticals Inc (KPRX) Institutional Confidence - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX) - The Globe and Mail
Kiora Pharmaceuticals (KPRX) Slips Slightly as Stock Hovers Near Key Support ZoneDouble Top - dars.gov.et
KPRX SEC FilingsKIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora Pharmaceuticals (KPRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Kiora Pharmaceuticals’ KIO-300 Shows Significant Seizure Suppression in Preclinical Epilepsy Model, Revealing Potential Beyond Ophthalmology 1 – Minichart - Minichart
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model - TMX Newsfile
Kiora Pharmaceuticals (NASDAQ: KPRX) reports KIO-300 epilepsy model data - Stock Titan
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):